Welcome to RealPatient DLBCL
RealPatient is your self-guided tour through published sources of CAR‑T real-world evidence and clinical trial data.
Select patient profiles of interest and view relevant real-world outcomes in specific populations in addition to clinical data. Latest data sources are updated regularly.
Disclaimer: This resource is an educational application only for worldwide healthcare professionals. It includes publicly available CAR‑T real-world evidence from large international and national registries and pivotal clinical trials.
© 2023 - www.cellcompass.com
Use of website governed by the Terms of Service and Privacy Policy. Copyright © 2023 Novartis AG. All rights reserved.
Who is your CAR‑T patient?
Tisagenlecleucel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
07/23 210636-2